🔎 Trials Near Me

홈 › 급성 림프모구성 백혈병 › 메릴랜드

메릴랜드의 급성 림프모구성 백혈병 임상 시험

급성 림프모구성 백혈병 관련 연구 16개가 메릴랜드 내 여러 지역에서 참여자를 모집하고 있습니다.

메릴랜드의 도시

공식 연구 텍스트(영어)

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1상
18세 ~ 120세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06904066

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1상
18세 ~ 120세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07572136

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • 외 10개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중2상
3세 ~ 65세 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07328503

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1/2상
3세 ~ 39세 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05442515

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
피험자 모집 중초기 1상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06398457

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241

Multicenter HomeVENT: Home Values and Experiences Navigation Track

  • Johns Hopkins University School of Medicine, Baltimore
피험자 모집 중건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06102330

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1/2상
18세 ~ 120세 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06364423

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Johns Hopkins, Baltimore
  • Nih/Niaid, Bethesda
  • Nih/Nhlbi, Bethesda
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 5. 18. 업데이트됨 · NCT01790152

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Sibley Memorial Hospital, Baltimore
  • University of Maryland, Baltimore
  • Johns Hopkins Main Center, Baltimore
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Maryland, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 11. 5. 업데이트됨 · NCT04260022

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Johns Hopkins University, Baltimore
  • National Cancer Institute, Pediatric Oncology Branch, Bethesda
피험자 모집 중1상
1세 ~ 21세 · 모든 성별 · 2024. 12. 6. 업데이트됨 · NCT05476770

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.